MARKET

MGTA

MGTA

Magenta Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.72
-0.31
-3.86%
After Hours: 7.72 0 -0.02% 16:29 09/18 EDT
OPEN
8.13
PREV CLOSE
8.03
HIGH
8.23
LOW
7.47
VOLUME
773.66K
TURNOVER
--
52 WEEK HIGH
16.19
52 WEEK LOW
5.76
MARKET CAP
372.51M
P/E (TTM)
-3.6328
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile

Analyst Price Target

The average MGTA stock price target is 18.50 with a high estimate of 22.00 and a low estimate of 15.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MGTA
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is developing therapeutics to transform hematopoietic stem cell transplants for patients with immune and blood-based diseases. It maintains a platform with integrated and modular approach, which aims to reboot the blood and immune systems. The Company’s products include MGTA-145, MGTA-456, E478, and G100. The Company also developing a pipeline of small molecules; biologics, including antibody drug conjugates; and a cell therapy, which transplant options for many more patients with autoimmune diseases, blood cancers and genetic diseases. The Company’s C100 program targets HSCs, immune cells, and disease-causing cells, the C200 program targets HSCs and disease-causing cells and the C300 program targets only immune cells. This is achieved by tuning the antibodies to specific cellular markers or receptors that are expressed on the particular cell types.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Magenta Therapeutics Inc stock information, including NASDAQ:MGTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGTA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MGTA stock methods without spending real money on the virtual paper trading platform.